The estimated Net Worth of Keith Holliday is at least $12.1 Milhão dollars as of 17 March 2023. Keith Holliday owns over 823 units of Staar Surgical Co stock worth over $837,556 and over the last 8 years he sold STAA stock worth over $10,227,200. In addition, he makes $1,072,830 as Chief Technology Officer at Staar Surgical Co.
Keith has made over 17 trades of the Staar Surgical Co stock since 2017, according to the Form 4 filled with the SEC. Most recently he sold 823 units of STAA stock worth $51,001 on 17 March 2023.
The largest trade he's ever made was selling 72,015 units of Staar Surgical Co stock on 14 September 2020 worth over $3,839,840. On average, Keith trades about 10,444 units every 84 days since 2017. As of 17 March 2023 he still owns at least 27,633 units of Staar Surgical Co stock.
You can see the complete history of Keith Holliday stock trades at the bottom of the page.
Dr. Keith Holliday, Ph.D. serves as Chief Technology Officer of the Company. Dr. Keith Holliday joined STAAR in August 2015 as Vice President of Research and Development. In March 2017, he assumed the role of the Chief Technology Officer. From 2007 to his arrival at STAAR, he served as Vice President, Research and Development at ReVision Optics where he oversaw the development of their corneal inlay technology that includes a hydrogel inlay for presbyopia correction, delivery devices and clinical methodologies as well as managing first-in-man clinical studies. Previously, he was Director of Laser Technology at Advanced Medical Optics (AMO) and Staff Laser Scientist at VISX. Prior to joining VISX, Dr. Holliday worked primarily in academia. He obtained his first degree in Physics and Electronics from the University of Saint Andrews in Scotland and a Ph.D. from the Laser Physics Centre at the Australian National University. He spent three years at the Swiss Federal Institute of Technology, where he was primarily involved with the utilization of optically active polymers and crystals, to develop materials and techniques for very high density, holographic optical storage and computational systems. Dr. Holliday holds patents in excimer laser beam detection, control and profiling, and methods to correct presbyopia that synergistically take into account the epithelium’s response to corneal inlays, and he has also authored 37 peer reviewed publications in the scientific literature plus two book chapters and one single-authored book. He is considered an expert on presbyopia and served as a committee member for the International Society of Presbyopia.
As the Chief Technology Officer of Staar Surgical Co, the total compensation of Keith Holliday at Staar Surgical Co is $1,072,830. There are 2 executives at Staar Surgical Co getting paid more, with Caren Mason having the highest compensation of $3,616,040.
Keith Holliday is 57, he's been the Chief Technology Officer of Staar Surgical Co since 2017. There are 14 older and 6 younger executives at Staar Surgical Co. The oldest executive at Staar Surgical Co. is John Moore, 76, who is the Independent Director.
Keith's mailing address filed with the SEC is 25651, Atlantic Ocean Drive, Lake Forest, Orange County, California, 92630, United States.
Over the last 21 years, insiders at Staar Surgical Co have traded over $305,974,767 worth of Staar Surgical Co stock and bought 10,576,326 units worth $122,359,752 . The most active insiders traders include Partners, L.P.Broadwood Cap..., Partners, L.P.Bradsher Neal..., eGilbert H Kliman. On average, Staar Surgical Co executives and independent directors trade stock every 26 days with the average trade being worth of $1,643,742. The most recent stock trade was executed by Arthur C Butcher on 12 August 2024, trading 1,315 units of STAA stock currently worth $49,957.
staar surgical company (nasdaq: staa), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye has been dedicated solely to ophthalmic surgery for over 30 years. the company offers the evo visian implantable collamer® lenses (icls) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia; and hyperopic icl, which treats far-sightedness. these lenses are intended to provide visual freedom for patients, lessening or eliminating the reliance on glasses or contact lenses. all of these lenses are foldable, which permits the surgeon to insert them through a small incision. staar's lens used in refractive surgery is called an implantable collamer lens or "icl". nearly 600,000 visian icls have been implanted to date. it also provides minimally invasive intraocular lenses (iols), including foldable iols for use in minimally invasive cataract surgical procedures; aspheric iols that produce a clearer image than trad
Staar Surgical Co executives and other stock owners filed with the SEC include: